FDA approves ADMA Biologics' ASCENIV for immune compromised children aged 2 and up

ADMA Biologics announced FDA approval to expand the label of its immune globulin product ASCENIV to include pediatric patients aged two years and older with primary humoral immunodeficiency (PI). Previously, ASCENIV was approved only for patients aged 12 and above. This approval allows earlier treatment for younger immune compromised children, potentially improving their health outcomes. ADMA plans to increase ASCENIV's use as a specialized treatment option for this vulnerable group.